


PRODUCT INFORMATION



INCB 28060

Item No. 20056

CAS Registry No.: 1029712-80-8
Formal Name: 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-benzamide
Synonyms: Capmatinib, INC 280
MF: C₂₃H₁₇FN₆O
FW: 412.4
Purity: ≥98%
UV/Vis.: λ_{max}: 228, 252, 303, 316, 383 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

INCB 28060 is supplied as a crystalline solid. A stock solution may be made by dissolving the INCB 28060 in the solvent of choice, which should be purged with an inert gas. INCB 28060 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of INCB 28060 in these solvents is approximately 0.30 and 1 mg/ml, respectively.

INCB 28060 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, INCB 28060 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. INCB 28060 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

INCB 28060 is an inhibitor of heptatocyte growth factor receptor (HGFR, also known as c-Met), potently blocking *in vitro* kinase activity (IC₅₀ = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC₅₀ values range from 0.3 to 1.1 nM).¹ It blocks cell proliferation and migration or induces apoptosis in different types of cancer cells.¹ INCB 28060 is orally bioavailable and inhibits the growth of HGFR-dependent tumors in mice.¹ It also improves efficacy of gemcitabine (Item No. 11690) in a mouse pancreatic cancer model and reduces migration and adhesion in ovarian cancer cell models.^{2,3}

References

1. Liu, X., Wang, Q., Yang, G., *et al.* A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. *Clin. Cancer. Res* **17(22)**, 127-138 (2011).
2. Brandes, F., Schmidt, K., Wagner, C., *et al.* Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. *BMC Cancer* **15:71**, (2015).
3. Moran-Jones, K., Brown, L. M., Samimi, G., INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models. *Sci. Rep.* **5:11749**, (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM